1. Home
  2. TBPH vs AVK Comparison

TBPH vs AVK Comparison

Compare TBPH & AVK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • AVK
  • Stock Information
  • Founded
  • TBPH 2013
  • AVK 2003
  • Country
  • TBPH United States
  • AVK United States
  • Employees
  • TBPH N/A
  • AVK N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • AVK Trusts Except Educational Religious and Charitable
  • Sector
  • TBPH Health Care
  • AVK Finance
  • Exchange
  • TBPH Nasdaq
  • AVK Nasdaq
  • Market Cap
  • TBPH 699.0M
  • AVK 561.1M
  • IPO Year
  • TBPH N/A
  • AVK N/A
  • Fundamental
  • Price
  • TBPH $14.40
  • AVK $12.61
  • Analyst Decision
  • TBPH Strong Buy
  • AVK
  • Analyst Count
  • TBPH 4
  • AVK 0
  • Target Price
  • TBPH $23.00
  • AVK N/A
  • AVG Volume (30 Days)
  • TBPH 543.4K
  • AVK 112.9K
  • Earning Date
  • TBPH 11-11-2025
  • AVK 01-01-0001
  • Dividend Yield
  • TBPH N/A
  • AVK 11.85%
  • EPS Growth
  • TBPH N/A
  • AVK N/A
  • EPS
  • TBPH 0.26
  • AVK N/A
  • Revenue
  • TBPH $77,205,000.00
  • AVK N/A
  • Revenue This Year
  • TBPH $79.82
  • AVK N/A
  • Revenue Next Year
  • TBPH N/A
  • AVK N/A
  • P/E Ratio
  • TBPH $55.89
  • AVK N/A
  • Revenue Growth
  • TBPH 24.49
  • AVK N/A
  • 52 Week Low
  • TBPH $7.88
  • AVK $9.24
  • 52 Week High
  • TBPH $14.55
  • AVK $12.16
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 72.80
  • AVK 60.69
  • Support Level
  • TBPH $13.47
  • AVK $12.42
  • Resistance Level
  • TBPH $14.42
  • AVK $12.75
  • Average True Range (ATR)
  • TBPH 0.41
  • AVK 0.08
  • MACD
  • TBPH -0.05
  • AVK 0.01
  • Stochastic Oscillator
  • TBPH 86.11
  • AVK 65.85

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About AVK Advent Convertible and Income Fund

Advent Convertible & Income Fund is a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in various sectors, such as communications, utilities, energy, industrial, technology, and others.

Share on Social Networks: